What is One-Day (ONE-D) TMS and How Does it Work?

PMH Seminar Series - Target Location Image One D TMS 1D TMS
  • Latest Development in Accelerated TMS: The ONE-D (Optimized, Neuroplastogen-Enhanced techniques in Depression) regimen, first described by Vaughn and colleagues in 2024, is designed to make TMS treatment faster, more affordable, and accessible.  It is given off-label: the TMS device is FDA-cleared, but the one-day schedule is not.

 

  • Accelerated Full Course: ONE-D delivers a patient's entire course of Transcranial Magnetic Stimulation (TMS) therapy, which conventionally takes weeks of visits, in a single day of about 10 hours.


  • Intensive, Spaced Sessions: The single-day treatment involves 20 sessions of high-intensity, 3-minute intermittent Theta-Burst Stimulation (iTBS), the iTBS pulse pattern also studied in Stanford's SAINT research, with sessions repeated every 30 minutes to allow for brain recovery and maximal plasticity.

 

  • Neuroplastogen Enhancement: The protocol is "Neuroplastogen-Enhanced," with a single pre-treatment dose of up to two medications, D-cycloserine and lisdexamfetamine (Vyvanse), to enhance the brain's ability to change (neuroplasticity) and improve the treatment's effect.

 

  • Targeting: The study involved targeted stimulation at the posterior left Dorsolateral Prefrontal Cortex (DLPFC) using a non-personalized, scalp-based method.  At Cognitive FX, we use a personalized target based on each patient's own fMRI scan. No study has tested that combination with the one-day schedule yet.

 

 

How our One-D day differs from the published protocol

 


 

  • Personalized Targeting: Standard TMS uses skull measurements to estimate where your brain's depression-related circuits should be, similar to how a tailor might use standard sizing. But just like everyone's body is different, everyone's brain connectivity is unique. fMRI-guided TMS maps your specific brain architecture before treatment, identifying the exact spot in your prefrontal cortex that shows the strongest connection to your depression networks.



 

 

DISCLAIMER: SAINT™ is a trademark of The Board of Trustees of the Leland Stanford Junior University (“Stanford”) and has exclusively licensed such mark to Magnus Medical. Cognitive FX is neither endorsed by Stanford nor utilizes Magnus Medical equipment nor claims to be offering the SAINT protocol as prescribed by Stanford University et. al. or Magnus Medical.  We provide fMRI guided intermittent theta burst TMS with target locations determined by fMRI and our prescribing physician. 

What the research shows so far

The one-day regimen was first described in 2024, in a review of 32 patients' charts at two private clinics (Vaughn et al.). A review of 8 patients in a primary care office followed in 2025 (Nanos). Neither study had a control group.

The Clinical TMS Society said in December 2025 that this evidence is preliminary and not yet enough to recommend one-day TMS over better-studied options. Read the statement.

Our version differs from the published one. We aim every session with your own fMRI scan, while the published studies used a scalp-based target. No study has tested that combination yet.

How ONE-D TMS is different from rTMS and SAINT TMS

1. How long does ONE-D TMS take compared to the different treatment options?

Conventional repetitive TMS (rTMS) is a proven treatment, but it often takes dozens of clinic visits over four to six weeks. ONE-D condenses the full course into a single 10-hour day (20 sessions, one every 30 minutes). That can make treatment workable for people who live far from a clinic, have trouble getting around, or can't take weeks off work for daily appointments.

2. How does ONE-D differ from other accelerated protocols like SAINT TMS?
  • Duration: ONE-D is a single-day (10-hour) treatment, whereas SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) is typically a 5-day course.

  • Targeting: SAINT uses personalized targeting via functional MRI (fMRI) to locate the exact stimulation site. ONE-D uses a validated, scalp-based heuristic target for the left posterior DLPFC, making the procedure more accessible and faster to set up.

  • Response Onset: A key finding of the ONE-D study was a delayed therapeutic response, with symptom improvement steadily increasing and reaching a plateau between weeks 4 and 6 post-treatment. This contrasts with the SAINT protocol, which reported a much more rapid response, with remission achieved in an average of 2.6 days.

  • SAINT is FDA-cleared as a system on Magnus Medical equipment. ONE-D uses an FDA-cleared TMS device, but the one-day schedule is not cleared, so it is given off-label.
3. What is "Neuroplastogen Enhancement," and is it unique to ONE-D?

The medication step is what sets ONE-D apart from other accelerated protocols. The published protocol adds a single pre-treatment dose of two medications, D-cycloserine (DCS) and lisdexamfetamine, about an hour before the first TMS session. Both are used off-label here. They are included to support neuroplasticity, the brain's ability to form new connections, which may increase the treatment's effect. Depending on your health history, our physician may use one or both. Conventional rTMS and SAINT typically do not include medication.

4. What does the research show so far?

The evidence is early. ONE-D was first described in a 2024 review of 32 patients' charts at two private clinics (Vaughn et al.), which tracked depression and anxiety scores for 12 weeks. An 8-patient review from a primary care office followed in 2025 (Nanos). Neither study had a control group or randomization, and no study has compared ONE-D head to head with multi-week rTMS.

The Clinical TMS Society's December 2025 statement says this evidence is preliminary and asks clinics to be clear about that. We agree, and our team will go over it with you at your consult.

5. Is the ONE-D protocol safe, and are the results long-lasting?

In the 2024 chart review of 32 patients, every patient completed all 20 sessions on schedule and no serious adverse events were reported. The most common side effects were brief scalp discomfort and headache during treatment or in the week after, which are common with any TMS. How long the benefit lasts is still an open question: the review followed patients for 12 weeks, and its authors note that randomized trials are needed. Our team will go over follow-up care with you.

6. Is ONE-D TMS covered by insurance?

Because the one-day schedule is not FDA-cleared, it is given off-label, and insurance plans generally don't cover it. We offer One-D as cash pay: $3,000 covers your fMRI scan and the treatment day.

Testimonial for fMRI-Guided TMS
Accelerated Transcranial Magnetic Stimulation Review

“The Most Impressive Therapy I’ve Ever Tried”: Tim Ferriss On Transcranial Magnetic Stimulation

Patient Reviews

TMS Articles

Learn more about different aspects of accelerated fMRI-guided TMS. See if treatment can help you live the life you want to live.

SAINT™ TMS in Los Angeles: Providers, Cost & a Lower-Cost Alternative
SAINT™ TMS in Los Angeles: Providers, Cost & a Lower-Cost Alternative
SAINT™ TMS in Phoenix: Providers, Costs & Why Targeting Matters
SAINT™ TMS in Phoenix: Providers, Costs & Why Targeting Matters
Your Brain Before and After TMS: What Imaging Actually Shows (and What It Doesn't)
Your Brain Before and After TMS: What Imaging Actually Shows (and What It Doesn't)
TMS vs. EMDR for Treating PTSD
TMS vs. EMDR for Treating PTSD
Deep TMS vs Accelerated TMS: Speed, Cost, and Remission
Deep TMS vs Accelerated TMS: Speed, Cost, and Remission

If you're in crisis or thinking about suicide, call or text 988 now. One-D is not an emergency treatment.

One-D is an off-label use of an FDA-cleared TMS device. The one-day schedule and the pre-treatment medications are not FDA-cleared or approved for depression.

Medically reviewed by Dr. Lynn Gaufin, MD, Director of Neurosurgery, on October 28, 2026.

DISCLAIMER: SAINT™ is a trademark of The Board of Trustees of the Leland Stanford Junior University (“Stanford”) and has exclusively licensed such mark to Magnus Medical. Cognitive FX is neither endorsed by Stanford nor utilizes Magnus Medical equipment nor claims to be offering the SAINT protocol as prescribed by Stanford University et. al. or Magnus Medical.  We provide fMRI guided intermittent theta burst TMS with target locations determined by fMRI and our prescribing physician.